Development Center for Biotechnology
Records under this name other than the patents Development Center for Biotechnology holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 47 patents it holds.
Back to Development Center for Biotechnology
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,961,971 | Bispecific T-Cell Activator Antibody Formerly held In force · High confidence | In force | High confidence | |
| US 9,428,575 | Anti-Granulysin Antibodies and Methods of Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 9,447,193 | Methods for Suppressing Cancer by Inhibition of TMCC3 Formerly held In force · High confidence | In force | High confidence | |
| US 9,750,804 | Alpha-enolase specific antibodies and method of use in immune diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,527,922 | Humanized Alpha-Enolase Specific Antibodies and Methods of Uses in Cancer Therapy Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,384,150 | Antibody-Drug Conjugates and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,499,139 | Targeted integration sites in Chinese hamster ovary cell genome Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,331,091 | Chimeric signal peptides for protein production Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,058,236 | Aqueous inhalation pharmaceutical composition Term ended Term ended May 25, 2026 · From the USPTO record | Term ended | Term ended May 25, 2026 | From the USPTO record |
| US 7,482,006 | Recombinant enterovirus 71 neutralizing antibodies and applications thereof Term ended Term ended Apr 17, 2026 · From the USPTO record | Term ended | Term ended Apr 17, 2026 | From the USPTO record |